Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00437112
Status:
COMPLETED
Last Update Posted:
2018-03-09
First Post:
2007-02-16
Brief Title:
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase 3 Open-Label Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder HIIP Compared With Once-Daily Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes Mellitus on Oral Agents
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to compare Human Inhalation Powder also known as AIR Inhaled Insulin AIR is a registered trademark of Alkermes Incwith insulin glargine injections in patients with Type 2 diabetes who are currently taking oral medications and have not previously taken insulin Change in HbA1c levels will be reviewed to determine superiority or inferiority of the AIR Inhaled Insulin regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H7U-MC-IDAZ | None | None | None |